Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping

Paolo Montuschi, Mario Malerba, Giuseppe Santini, Marc Miravitlles

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

45 Citazioni (Scopus)

Abstract

Chronic obstructive pulmonary disease (COPD) is characterized by large phenotype variability, reflected by a highly variable response to pharmacological treatment. Nevertheless, current guidelines suggest that patients with COPD of similar severity should be treated in the same way. The phenotype-based pharmacotherapeutic approach proposes bronchodilators alone in the nonfrequent exacerbator phenotype and a combination of bronchodilators and inhaled corticosteroids in patients with asthma-COPD overlap syndrome (ACOS) and moderate-to-severe exacerbator phenotype. The clinical importance of phenotypes is changing the paradigm of COPD management from evidence-based to personalized medicine. However, the personalized pharmacological strategy of COPD has to be validated in future clinical studies
Lingua originaleEnglish
pagine (da-a)1928-1935
Numero di pagine8
RivistaDrug Discovery Today
Volume19
DOI
Stato di pubblicazionePubblicato - 2014

Keywords

  • Asthma-COPD overlap syndrome
  • Chronic obstructive pulmonary disease (COPD)
  • Evidence-based medicine
  • Inhaled corticosteroids
  • Personalised pharmacological treatment
  • Pharmacotherapy
  • Phenotyping

Fingerprint Entra nei temi di ricerca di 'Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping'. Insieme formano una fingerprint unica.

Cita questo